ARQT Q3'26 Earnings: EPS estimate is 0.18 USD

What happened

Arcutis Biotherapeutics is scheduled to report third-quarter 2026 results on November 4 after the market closes, with disclosure expected at 4:00 p.m. ET. The supplied estimate is revenue of $142.59 million and earnings per share, or profit allocated to each share, of $0.18.

Confirmed

Global impact / market context

The results will show whether reported sales and profit per share meet the supplied expectations. A shortfall could weigh on investor views of the company’s ability to generate revenue and earnings, while stronger results could support confidence, though the article gives no forecast for the share-price response.

Analyst inference

The article lists estimates but no Q3 2026 results, guidance, or explanation of expected growth. Its table shows earlier reported revenue and per-share earnings, but those figures alone do not establish why analysts expect the upcoming quarter’s revenue and earnings to change.

Analyst inference

What to watch

1. Check the November 4 release for actual revenue against the $142.59 million estimate; the difference will show whether sales met, exceeded, or missed expectations. Confirmed
2. Compare reported earnings per share with the $0.18 estimate, and review any company explanation of results; the article does not provide actual Q3 2026 figures. Confirmed
3. Look for any guidance about future sales or spending, which could indicate whether results change expected revenue or costs; no such guidance appears in the supplied article. Analyst inference

Evidence

• Original source link unavailable